Literature DB >> 17678835

A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ).

Theodore Pincus1, Yusuf Yazici, Martin Bergman, Ross Maclean, Timothy Harrington.   

Abstract

A continuous quality improvement approach is proposed for the assessment and management of patients with rheumatoid arthritis (RA) based on scores on a one-page patient self-report multidimensional health assessment questionnaire (MDHAQ), without formal joint counts. The approach includes five simple steps before the patient is seen by the physician: (1) an MDHAQ is completed by every patient at every visit; (2) scores are calculated for patient function, pain, and global estimate, with options for a self-report joint count and other scales; (3) scores are entered on flow sheets with data from prior visits, which might also include laboratory and medication information; (4) scores are compiled into an index termed Routine Assessment of Patient Index Data (RAPID), analogous to a Disease Activity Score (DAS); (5) RAPID scores are classified to guide treatment decisions. RAPID 3 includes the three patient-reported outcome (PRO) measures in the RA Core Data Set - physical function, pain, and global estimate. RAPID 4 adds a self-report joint count, and RAPID 5, a physician global estimate. RAPID 3 can be calculated in about 10 seconds, RAPID 4 in about 19 seconds, and RAPID 5 in about 20 seconds. RAPID 3, RAPID 4, and RAPID 5 give similar results to distinguish active from control treatments in RA clinical trials, at levels similar to American College of Rheumatology or DAS improvement criteria, and are all correlated significantly with DAS28 (rho=0.62-0.64, P<0.001). A proposed classification of RAPID scores, analogous to four DAS28 categories, includes: 'near remission' (0-1), 'low severity' (1.01-2), 'moderate severity' (2.01-4), and 'high severity' (>4). RAPID scoring is feasible in standard clinical care to support continuous quality improvement.

Entities:  

Mesh:

Year:  2007        PMID: 17678835     DOI: 10.1016/j.berh.2007.02.009

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  21 in total

1.  Subjective numeracy and preference to stay with the status quo.

Authors:  Liana Fraenkel; Meaghan Cunningham; Ellen Peters
Journal:  Med Decis Making       Date:  2014-04-23       Impact factor: 2.583

2.  Decision tool to improve the quality of care in rheumatoid arthritis.

Authors:  Liana Fraenkel; Ellen Peters; Peter Charpentier; Blair Olsen; Lanette Errante; Robert T Schoen; Valerie Reyna
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-07       Impact factor: 4.794

3.  Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis.

Authors:  Michael M Ward; Isabel Castrejon; Martin J Bergman; Maria I Alba; Lori C Guthrie; Theodore Pincus
Journal:  J Rheumatol       Date:  2018-10-15       Impact factor: 4.666

4.  Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis.

Authors:  Abhijeet Danve; Anusha Reddy; Kiana Vakil-Gilani; Neha Garg; Alexis Dinno; Atul Deodhar
Journal:  Clin Rheumatol       Date:  2014-11-26       Impact factor: 2.980

5.  Interplay between patient global assessment, pain, and fatigue and influence of other clinical disease activity measures in patients with active rheumatoid arthritis.

Authors:  Emilie Lund Egsmose; Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2015-05-19       Impact factor: 2.980

6.  High disease activity may not be sufficient to escalate care.

Authors:  Liana Fraenkel; Meaghan Cunningham
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-02       Impact factor: 4.794

7.  Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria.

Authors:  Ole Rintek Madsen
Journal:  Clin Rheumatol       Date:  2016-06-09       Impact factor: 2.980

8.  The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.

Authors:  Fausto Salaffi; Marina Carotti; Stefania Gasparini; Michele Intorcia; Walter Grassi
Journal:  Health Qual Life Outcomes       Date:  2009-03-18       Impact factor: 3.186

9.  The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.

Authors:  Burkhard F Leeb; Elke Böttcher; Hans-Peter Brezinschek; Christoph Czerwenka; Manfred Herold; Hans Hitzelhammer; Franz Mayrhofer; Rudolf Puchner; Franz Rainer; Bernhard Rintelen; Michael Schirmer; Ulrike Stuby; Hans Bröll
Journal:  Clin Rheumatol       Date:  2009-11-11       Impact factor: 2.980

10.  Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients.

Authors:  Michel de Bandt; Bruno Fautrel; Jean Francis Maillefert; Jean Marie Berthelot; Bernard Combe; René-Marc Flipo; Frédéric Lioté; Olivier Meyer; Alain Saraux; Daniel Wendling; Xavier Le Loët; Francis Guillemin
Journal:  Arthritis Res Ther       Date:  2009-10-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.